SKYE
Skye Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.92
+7.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 172.9K | 723.4K | — | — | — |
| Gross Profit | (172.9K) | (723.4K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 32.5M | 42.4M | 18.7M | 5.8M | 6.0M |
| SG&A Expense | 15.9M | 15.8M | 17.7M | 7.9M | 6.1M |
| General & Admin Expense | 15.9M | 15.8M | 17.7M | 7.9M | 6.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 3.3M | (723.4K) | (6.2M) | 21.1M | 6.2M |
| Total Operating Expenses | 51.7M | 57.4M | 30.2M | 34.7M | 18.3M |
| Cost and Expenses | 51.9M | 58.2M | 30.2M | 34.7M | 18.3M |
| Operating Income (EBIT) | (51.9M) | (58.2M) | (30.2M) | (34.7M) | (18.3M) |
| Non-Operating | |||||
| Interest Income | 862.2K | 1.9M | 3.3M | 100.0K | 19.0K |
| Interest Expense | 5.5K | — | 967.6K | 906.3K | 663.8K |
| Net Interest Income | 856.7K | 1.9M | 2.3M | (806.3K) | (644.8K) |
| Other Non-Op Income/Expense | 1.4M | 2.2M | 3.6M | (2.9M) | (1.2M) |
| Non-Operating Income (excl Interest) | (1.4M) | (2.2M) | (4.6M) | 2.0M | 499.4K |
| EBT (Pre-Tax Income) | (50.5M) | (55.9M) | (26.6M) | (37.6M) | (19.5M) |
| Income Tax Expense | 3.4K | 5.4K | 10.1K | 3.6K | 6.7K |
| Bottom Line | |||||
| Net Income | (50.5M) | (55.9M) | (26.6M) | (37.6M) | (19.5M) |
| Earnings from Cont. Ops | (50.5M) | (55.9M) | (26.6M) | (37.6M) | (19.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (50.5M) | (55.9M) | (26.6M) | (37.6M) | (19.5M) |
| Per Share | |||||
| Basic EPS | ($10.16) | ($11.28) | ($5.84) | ($42.96) | ($70.16) |
| Diluted EPS | ($10.16) | ($11.28) | ($5.84) | ($42.96) | ($70.16) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.0M | 5.0M | 4.6M | 875750 | 277635 |
| Diluted Shares Outstanding | 5.0M | 5.0M | 4.6M | 875750 | 277635 |
| Profitability Metrics | |||||
| EBITDA | (50.0M) | (55.2M) | (25.3M) | (36.6M) | (18.7M) |
| D&A | 531.8K | 723.4K | 298.6K | 124.3K | 115.0K |
| EBIT | (50.5M) | (55.9M) | (25.6M) | (36.7M) | (18.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026